Orforglipron vs HGH Fragment 176-191.

Orforglipron (brand: Foundayo, development code LY3502970) is a once-daily, orally administered GLP-1 receptor agonist developed by Eli Lilly. The FDA approved it on 1 April 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. It is included on this site despite not being a peptide: orforglipron is a small-molecule, non-peptide agonist of the same receptor the injectable GLP-1 peptides target, and it is the closest direct alternative to them, so leaving it out would misrepresent the landscape people are actually choosing between.

HGH Fragment 176-191 is a synthetic peptide corresponding to the final 16 amino acids (residues 176 to 191) of the C-terminal region of human growth hormone. It derives from the observation that this domain appears to carry GH's fat-metabolizing (lipolytic) activity while lacking the growth-promoting and insulin-antagonizing actions of the whole hormone. It is closely related to, but distinct from, AOD-9604, a modified analog in which a tyrosine residue is added to the N-terminus (developed under the name Anti-Obesity Drug 9604). The plain 176-191 fragment itself is a research-only compound with almost no dedicated clinical data.

Orforglipron binds and activates the GLP-1 receptor, the same class B G-protein-coupled receptor engaged by semaglutide, liraglutide and the GLP-1 arm of tirzepatide, producing glucose-dependent insulin secretion, slowed gastric emptying, suppressed glucagon and reduced appetite. The pharmacologically interesting part is how it does this without being a peptide. Work published in Science Translational Medicine (2024, PMID 39693407) characterises the basis for non-peptide agonism at this receptor: the molecule occupies a site that permits receptor activation from a small synthetic scaffold rather than mimicking the native hormone's full peptide sequence. Because it is not a peptide, it is not degraded in the gut the way oral peptide formulations are, which is why it can be taken as a conventional tablet with no food or water timing restrictions, unlike oral semaglutide.

The proposed mechanism is stimulation of lipolysis, the breakdown of stored triglycerides, along with reduced fat synthesis in adipose tissue, reproducing the fat-reducing effect of GH's C-terminus without activating the GH receptor to raise IGF-1 or impair glucose handling. Work on the analog AOD-9604 implicated the beta-3-adrenergic pathway in this effect. The mechanism is characterized mainly in mouse and in vitro models, and how faithfully the unmodified 176-191 fragment reproduces it in humans is not established.

Human evidence is substantial and spans phase 2 through phase 3 in both obesity and type 2 diabetes. A phase 2 trial in adults with obesity (NEJM 2023, PMID 37351564) established dose-dependent weight reduction, and a parallel phase 2 programme in type 2 diabetes reported in The Lancet (2023, PMID 37369232) showed reductions in HbA1c and body weight. Phase 3 results in obesity were published in the New England Journal of Medicine (2025, PMID 40960239), and a separate NEJM report (2025, PMID 40544435) covered early type 2 diabetes. A head-to-head trial against oral semaglutide in adults with type 2 diabetes appeared in The Lancet (2026, PMID 41765029), and a randomized phase 3 maintenance trial was published in Nature Medicine (2026, PMID 42120723). ACHIEVE-5, adding orforglipron to titrated insulin glargine, was reported in JAMA (2026, PMID 42251769). This is a considerably more complete human evidence package than almost anything else discussed in peptide communities, which is the point worth taking from it.

Almost all supportive data come from the modified analog AOD-9604 rather than from 176-191 itself. Heffernan et al., in Endocrinology (2001, PMID 11713213), showed that AOD9604 reduced body weight and increased lipolysis in obese mice and that the effect disappeared in beta-3-adrenergic-receptor knockout mice, implicating that pathway. That was a rodent study using genetically obese and knockout strains, with short treatment periods and body-weight and tissue endpoints rather than clinical outcomes. Its central finding, dependence on a receptor whose contribution to human fat metabolism is far smaller than in rodents, is itself a reason to doubt direct translation. AOD-9604 was later carried into human obesity trials but did not produce clinically meaningful weight loss beyond placebo and was not approved as a drug. The program, run by an Australian sponsor, was discontinued after the larger placebo-controlled trial failed to separate from placebo on weight, which is the endpoint that matters for an anti-obesity indication. The compound was subsequently repositioned toward non-pharmaceutical uses, and a separate strand of published work examined intra-articular AOD9604 in a rabbit osteoarthritis model rather than obesity, which says nothing about systemic fat loss. For the unmodified 176-191 fragment specifically there is essentially no controlled human evidence, and its reputation is extrapolated from AOD-9604 data. The tyrosine added to the N-terminus of AOD-9604 was a deliberate stability modification, so the two molecules are not interchangeable, and no published head-to-head comparison establishes that the plain fragment behaves like the analog in people. The contrast with full-length somatropin is instructive: recombinant GH has approved indications, product labeling, decades of registry data, and a well-mapped metabolic profile, while the fragment has none of that. There are no human pharmacokinetic data for 176-191, no bioavailability data, no dose-ranging work, no imaging-based body-composition endpoints, and no long-term study of any kind.

The adverse-event profile reported across the trials is the familiar GLP-1 class pattern, dominated by gastrointestinal effects: nausea, vomiting, diarrhoea and constipation, generally most pronounced during dose escalation and often diminishing with time. Discontinuation for gastrointestinal reasons occurred in the trials. As an approved product it carries a prescribing label with the full contraindication and warning set for the GLP-1 receptor agonist class, and that label, not this page, is the authoritative safety document. Because it is a prescription medicine, safety monitoring happens through a prescriber rather than self-management, which is a meaningful difference from the research-use-only compounds elsewhere on this site.

In its trials the analog AOD-9604 was generally well tolerated over short periods, with headache and mild edema among the reported effects, but the plain 176-191 fragment has no comparable human safety record of its own. Long-term safety is unknown. The theoretical selling point of the fragment, that it separates GH's lipolytic action from the growth-promoting and insulin-antagonizing actions of the whole hormone, has never been confirmed in a controlled human study, so the assumption that it avoids GH's metabolic liabilities remains an assumption rather than a finding. Full-length growth hormone reliably raises IGF-1 and can worsen glucose tolerance and cause fluid retention, carpal tunnel symptoms, and arthralgia. Whether a C-terminal fragment is genuinely free of those effects at meaningful exposure is untested, and no study has measured IGF-1 or glucose handling during sustained exposure to the fragment. Because the peptide is administered by injection, the usual injection risks apply: local reactions, infection from non-sterile technique or non-sterile product, and immune response to a foreign fragment. Nothing published characterizes immunogenicity for this sequence. Injectable material sold online as Fragment 176-191 is unregulated research-grade product of uncertain identity and purity, frequently supplied without a certificate of analysis or with one that cannot be traced to the vial in hand, and independent testing of this market has found mislabeled and contaminated product. A proper trial would require fasting glucose and insulin, IGF-1, and lipid monitoring, together with sterility and endotoxin testing of the material, none of which happens outside a regulated setting. The safety of the fragment itself remains largely uncharacterized.

FDA-approved 1 April 2026 as Foundayo (orforglipron) for chronic weight management in adults with obesity, or with overweight plus at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity. It is a prescription medicine. Approval is indication-specific: an approval for chronic weight management is not a validation of any other use it may be marketed or discussed for. Regulatory status elsewhere in the world varies and should be checked locally.

HGH Fragment 176-191 is not an approved drug and is sold as research-use-only. The related AOD-9604 was investigated for obesity, failed to reach approval as a pharmaceutical, and was subsequently pursued as a food and cosmetic ingredient in some markets; neither has FDA approval as a weight-loss medicine. GH fragments of this type are prohibited in sport by WADA.